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 VCP, a Major ATPase in the Cells, as a Novel 
Drug Target for Currently Incurable 
Disorders 
 Akira  Kakizuka 
 Abstract  Neuroprotection would be a novel therapeutic strategy for the prevention 
or retardation of clinical manifestations of currently incurable eye diseases as well 
as neurodegenerative diseases. A decrease in cellular ATP levels may contribute to 
the pathologies of these diseases; therefore, stabilization of ATP levels may retard 
the disease progression. We created novel small compounds (Kyoto University 
Substances, KUSs) to inhibit the ATPase activity of VCP (valosin-containing 
protein), the most abundant soluble ATPase in the cell. KUSs did not apparently 
impair the reported cellular VCP functions. Nevertheless, they signiﬁ cantly suppressed 
the VCP-dependent decrease of cellular ATP levels. Moreover, KUSs as well as 
exogenous ATP or ATP-producing compounds suppressed endoplasmic reticulum 
(ER) stress, and indeed protected various types of cultured cells from cell death-
inducing insults. We then examined the efﬁ cacies of KUSs in rd10, a mouse model 
of retinitis pigmentosa. KUSs not only prevented photoreceptor cell death but also 
preserved visual function. These results reveal an unexpected, crucial role of ATP 
consumption by VCP for the determination of cell fate in the pathological context, 
and point to a promising new neuroprotective strategy for currently incurable eye 
and neurodegenerative diseases. 
 Keywords  VCP •  ATP regulation •  Incurable diseases •  Retinitis pigmentosa •  ER 
stress •  Cell death •  Drug discovery 
 Background 
 Despite recent advances in medical care, there remain many incurable disorders, 
e.g. neurodegenerative diseases, incurable eye diseases, etc. In these disorders, the 
major pathology is early cell death in the affected organs, which precedes the 
death of the individual, often affecting the quality of life over extended periods. 
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To date, no drug has been successful at inhibiting or delaying such early cell death 
in vivo. In the 1990s, with much optimism, caspase inhibitors were developed and 
were expected to be such miracle drugs, but they were not able to prevent cell death 
in vivo. Indeed, later research revealed that caspases determine how cells die but are 
not able to affect the commitment to cell death. 
 Retinitis pigmentosa, in which a gradual degeneration and loss of photoreceptors 
occur along with aging, causes severe visual deterioration, and more than 1.5 million 
patients worldwide are estimated to be suffering from this eye disorder. There is no 
effective treatment that can prevent or delay the symptoms of retinitis pigmentosa. 
At least 60 genes have been implicated in retinitis pigmentosa, and therefore the 
cellular etiology—that is, the constellation of cellular mishaps that culminate in cell 
death—is the subject of ongoing debate. Involvement of endoplasmic reticulum (ER) 
stress has been proposed as a pathological mechanism in retinitis pigmentosa [ 1 ,  2 ]. 
 VCP in Neurodegenerative Disorders 
 Using polyglutamine disease models, we have long been searching for common 
molecular bases in neurodegenerative diseases, and have found valosin-containing 
protein (VCP), an AAA (ATPases Associated with diverse cellular Activities)-type 
ATPase with ubiquitous expression, as a major player causing neurodegeneration. 
VCP is a phylogenetically well-conserved protein, and the respective amino acid 
sequences are identical among mouse, rat, and human, and 84 % identical between 
human and  Drosophila [ 3 ]. To search for modiﬁ er genes that are involved in the 
pathogenesis of polyglutamine diseases, we ﬁ rst created  Drosophila models of 
polyglutamine diseases, and then performed genetic analyses. In 2002, our mutant 
screening revealed that  Ter94 loss-of-function alleles mitigated eye degeneration 
that was induced by the expression of genes with expanded polyglutamine tracts [ 3 ]. 
Consistent with these results, overexpression of wild-type  Ter94 exacerbated the 
polyglutamine-induced eye degeneration [ 3 ]. It is notable that the mammalian  Ter94 
ortholog is  VCP . Thus, these results implicated VCP in the pathogenesis of human 
neurodegenerative diseases [ 4 ]. In 2004 and 2010, VCP mutations were identiﬁ ed 
that are causative for IBMPFD (inclusion body myopathy associated with Paget 
disease of bone and frontotemporal dementia) [ 5 ], a human hereditary disease with 
dementia, and for rare cases of familial amyotrophic lateral sclerosis (ALS) [ 6 ], 
respectively. In our evaluation, all tested pathogenic VCPs showed signiﬁ cant eleva-
tions of the ATPase activities, as compared with wild-type VCP [ 7 ], and thus we 
proposed the possibility that the constitutive elevation of its ATPase activity is a 
pathogenic mechanism. 
 These lines of evidence suggested that speciﬁ c inhibitors of the ATPase activity 
of VCP could protect neuronal cells. In addition to its ATPase activity, however, 
VCP has been proposed to act in many important cellular processes [ 8 – 10 ], 
e.g., proteasome-mediated protein degradation, endoplasmic reticulum-associated 
degradation (ERAD), cell cycle control, membrane fusion, maintenance of the 
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Golgi apparatus, protein trafﬁ cking, autophagy, genomic DNA surveillance, etc. 
Indeed, VCP knockdown and overexpression of dominant-negative forms of 
VCP induced cell death in essentially all cultured cells [ 11 ,  12 ]. DBeQ, a recently 
reported VCP inhibitor (with an in vitro IC50 of 1 μM) [ 13 ], also induced cell death. 
Among the diverse cellular functions of VCP, some would require ATP hydrolysis 
and others would not. Thus, we believed it would be possible to ﬁ nd or develop 
small compounds that can inhibit or reduce the ATPase activity of VCP without 
inducing cellular toxicity. 
 Development of Novel Inhibitors (KUSs) of VCP ATPase 
Activity That Do Not Block VCP Cellular Functions 
 In our screening for novel VCP ATPase inhibitors, we found that a naphthalene 
derivative can inhibit the ATPase activity of VCP without showing apparent toxicity 
in cultured cells. Via the modiﬁ cation of its chemical structure, we created about 
200 new compounds and named them Kyoto University Substances (KUSs). Some 
of them clearly inhibited the ATPase activity of recombinant VCP in vitro with IC 50 
values ranging from approximately 100 nM to 1 μM (Fig.  1 ). Importantly, the KUSs 
did not appear to inhibit the ATPase activity of N-ethylmaleimide-sensitive fusion 
protein (NSF), the protein most closely related to VCP.
 As reported, DBeQ induced accumulation of ubiquitinated proteins, ER stress, 
autophagy, and eventually cell death. In contrast, KUSs (e.g. KUS31, 69, 94, 121, 
and 187) did not induce any of these phenotypes. These results clearly indicated that 
ATPase inhibition by KUS31, 69, 94, 121, and 187 (referred to as “KUSs” hereafter) 
did not interfere with reported cellular VCP functions (referred to as “VCP functions” 







































 Fig. 1  Structures and IC 50  values of Kyoto University Substances (KUSs), novel valosin- 
containing protein (VCP) modulators (Modiﬁ ed from Ikeda et al. [ 22 ]). Structures and IC 50 values 
of KUS11, KUS31, KUS69, KUS94, KUS121, and KUS187 are shown. Note that KUS11 did not 
inhibit the ATPase activity of recombinant VCP, and it did not share a common structure with the 
other KUSs 
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 KUSs Protected Cells Under ER Stress-Inducing Conditions 
 Over and above their lack of toxicity, KUSs were found to protect cells from several 
cell death-inducing insults. For example, HeLa cells died within several days when 
cultured under low-glucose conditions (0.2 g/l of glucose) (Fig.  2a ). However, the 
addition of KUSs prevented cell death under these conditions (Fig.  2a, b ). Similar 
protective effects were also observed when HeLa cells were cultured with tunica-
mycin (Tm) (Fig.  2c ), or when HEK293 cells were cultured under serum-free 
conditions (Fig.  2d ). These data indicated that inhibition of VCP ATPase activity by 
KUSs was beneﬁ cial for cells against cell death–inducing insults.
 Tunicamycin treatment and glucose starvation cause ER stress and eventually 
lead to cell death. C/EBP-homologous protein (CHOP) is upregulated during ER 
stress, and is proposed to mediate the ER stress-induced cell death [ 14 ]. Indeed, the 
induction of CHOP in tunicamycin-treated HeLa cells was suppressed by the addi-
tion of KUSs. The induction of 78 kDa glucose-regulated protein (Grp78), another 
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 Fig. 2  Prevention of cell death and endoplasmic reticulum (ER) stress by Kyoto University 
Substances (KUSs) (Modiﬁ ed from Ikeda et al. [ 22 ]). ( a ) Photographs of HeLa cells, cultured with 
DMSO (DMSO) or KUSs (KUS94, KUS121, and KUS187, 20 μM each) for 41 h in low- glucose 
(0.2 g/l) medium. Scale bar, 100 μm. ( b ,  c ) WST (water-soluble tetrazolium salt) values reﬂ ecting 
relative live cell numbers are shown as optical density (OD) at 450 nm.  Error bars indicate stan-
dard deviations. ( b ) WST values of HeLa cells, cultured in low glucose (0.2 g/l) with DMSO (D) 
or KUSs (50 μM for KUS121; 20 μM for KUS69, KUS94, and KUS187;  n = 3) for 41 h. ( c ) Cell 
viability, indicated by WST values of HeLa cells, cultured with tunicamycin (Tm) (0.2 μg/ml) for 
41 h with DMSO (D) or KUSs (20 μM each;  n = 3). ( d ) WST values of HEK293 cells, cultured 
under serum-free conditions for 65 h with DMSO (D) or KUSs (20 μM each;  n = 3). *** P < 0.001 




These data indicate that KUSs have the ability to suppress ER stress and to promote 
cell survival in certain conditions. 
 We next examined the effect of KUSs on cellular ATP levels. After a 20 h incubation 
in low-glucose medium (0.25 g/l), glucose levels in the medium approached zero, 
and ATP levels in the cells (control cells) also signiﬁ cantly decreased. In contrast, 
ATP levels in cells cultured in low-glucose medium and KUSs remained signiﬁ -
cantly higher than those in the control cells. 
 KUSs or Exogenous ATP Prevented ER Stress 
in Cultured Cells 
 ER stress has been believed to be induced by the accumulation of misfolded 
proteins, or protein aggregates, in the ER [ 16 – 18 ]. We recently identiﬁ ed laminin γ1 
as an aggregation-prone protein in the ER. We therefore examined the change of 
laminin γ1 states in ER stress by tunicamycin treatments. Expression of laminin 
γ1 was diffusely observed throughout the ER in normal cells (Control in Fig.  3a ). 
In tunicamycin- treated cells, laminin γ1 formed clear aggregates (DMSO in Fig.  3a ). 
However, 50 μM KUSs (KUS69, 94, 121, and 187) or 1 mM ATP treatments 
prevented its aggregation (Fig.  3a ). The KUSs or ATP treatment similarly prevented 
decreases of ATP levels in tunicamycin-treated cells (Fig.  3b ). By contrast, KUS11, 
which could not inhibit VCP ATPase, was unable to prevent the tunicamycin- 
elicited drop in cellular ATP concentration (Figs.  1 and  3b ). The addition of 0.1 mM 
ATP or 3 to 10 mM methylpyruvate (weakly membrane-permeable pyruvate, which 
is converted to ATP in mitochondria) was also ineffective in preventing the aggrega-
tion of laminin γ1 in tunicamycin-treated cells (Fig.  3a ), but could nevertheless 
suppress the induction of ER stress, namely CHOP induction (Fig.  3c ). These results 
indicated that the ER is more sensitive to decreases in ATP levels than to the presence 
of aggregates.
 KUSs Mitigated Pathologies of rd10, a Mouse 
Model of Retinitis Pigmentosa 
 We have long been seeking a new strategy to protect retinal neuronal cells. In retinitis 
pigmentosa, an involvement of ER stress has been proposed [ 1 ,  2 ]. We wondered 
whether the protective effects of KUSs in cell culture would translate  in vivo to the 
prevention of degeneration of photoreceptor cells in rd10 mice, a representative 
mouse model of retinitis pigmentosa [ 19 ]. Rd10 mice carry a mutation in a gene 
encoding the rod cyclic guanosine monophosphate (cGMP) phosphodiesterase beta 
subunit (PDE6B) [ 19 ]. Similar mutations are found in patients with retinitis 
pigmentosa. 
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 Starting 7 days after birth, KUS121 or KUS187 was administered daily (50 mg/kg) 
by intraperitoneal injection. Spectral-domain optical coherence tomography 
(SD-OCT) examination showed that at age 25 days, the thinning of the outer nuclear 
layer (ONL) was clearly observed in the control rd10 mice (Fig.  4a ). The ONL and 
the junction line between the inner segment and outer segment (arrow heads in 
Fig.  4a ), which is generally considered to be positively associated with visual function 
[ 20 ,  21 ], were clearly detected in the KUS-treated rd10 mice but not in control rd10 
mice. A very small electroretinogram response was observed in control rd10 mice, 
but an almost normal electroretinogram response was observed in most of the 
KUS- treated rd10 mice (Fig.  4b ). At age 29 days, the photoreceptor layer was barely 
 Fig. 3  Kyoto University Substances (KUSs) and ATP each prevented a decrease of ATP levels and 
ameliorated endoplasmic reticulum (ER) stress in tunicamycin (Tm)-treated cells (Modiﬁ ed from 
Ikeda et al. [ 22 ]). ( a ) Immunocytochemical analyses of HeLa cells by an anti- laminin γ1 antibody. 
HeLa cells were treated with 0.5 μg/ml of Tm for 5 h in the presence of KUSs (50 μM), ATP (0.1, 
0.3, and 1 mM), methylpyruvate (MePyr) (3 and 10 mM), or vehicle alone (DMSO). Then, cells 
were ﬁ xed and subjected to immunocytochemical analyses. Normally growing HeLa cells were 
also analyzed (Control). Scale bar, 10 μm. ( b ) Measurements of the relative amounts of ATP per 
cell. HeLa cells were treated with Tm (0.5 μg/ml) for 24 h in the presence of KUSs (50 μM) or ATP 
(0.1 and 1 mM), or vehicle alone (DMSO), and were harvested. Then, ATP amounts from 1.5 × 10 5 
cells were measured. * P < 0.05, ** P < 0.01.  Error bars indicate standard deviations. ( c ) Western 
blot analyses of C/EBP-homologous protein (CHOP). HeLa cells were treated with 0.5 μg/ml of 
Tm for 5 h in the presence of KUSs (50 μM), ATP (0.1, 0.3, and 1 mM), MePyr (3 and 10 mM), or 
vehicle alone (-). Then, cells were harvested and subjected to western blot analyses. Actin served 




detected in SD-OCT images, and electroretinogram records were almost ﬂ at in control 
rd10 mice. In the age-matched KUS-treated rd10 mice, the ONL, although thin, and 
an electroretinogram response were still observed (Fig.  4c, d ).
 By histological examination, at age 33 days, the ONL in the control rd10 mice 
consisted of only 1–2 rows of cells, but there remained 5–6 rows of cells in the ONL 
in the KUS-treated rd10 mice (Fig.  4e ). In KUS-treated mice but not in control rd10 
mice, the outer segment of the photoreceptors was observed (Fig.  4e ). The electro-
retinogram was non-recordable in the control rd10 mice, but small b-wave and 
oscillatory potentials were observed in the KUS-treated rd10 mice (Fig.  4f ). Time- 
dependent changes in total retinal thickness measured on SD-OCT images (Fig.  4g ) 
and in b-wave amplitudes of dark-adapted electroretinograms (Fig.  4h ) showed that 
rd10 rd10
 Fig. 4  In vivo efﬁ cacies of Kyoto University Substances (KUSs) in the rd10 mouse model of reti-
nitis pigmentosa (Modiﬁ ed from Ikeda et al. [ 22 ]). ( a ,  c ) Representative live sectional images 
( vertical sections ) by spectral-domain optical coherence tomography (SD-OCT) of retinas in 
25-day-old ( a ) and 29-day-old ( c ) normal C57BL/6 mice (WT) and rd10 mice, administered KUS 
121 ( n = 17), KUS187 ( n = 21), or saline ( n = 18) as a control.  Vertical bars in the images indicate 
the thickness of the outer nuclear layer (ONL). Note that the ONL was barely detectable in saline-
treated control rd10 mice. ( b ,  d ,  f ) Electroretinograms of 25-day-old ( b ), 29-day-old ( d ), and 
33-day-old ( f ) normal C57BL/6 mice (WT) and rd10 mice, administered KUSs or saline. ( e ) 
HE-stained retinas of 33-day-old normal C57BL/6 mice (WT) and rd10 mice, administered KUSs 
or saline. Scale bars (shown by  white color ), 100 μm in ( a) and ( c ); 20 μm in ( e ). ( g ,  h ) Time- 
dependent changes of total retinal thickness ( g ) and b-wave amplitude in dark-adapted electroreti-
nograms ( h ) in rd10 mice administered KUSs or saline (C). * P < 0.05, ** P < 0.01, *** P < 0.005 vs. 
saline (Dunnett’s test).  Error bars indicate standard deviations.  OS outer segment,  RPE retinal 
pigment epithelium 
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KUS treatments had the potential to prevent or delay the disease progression. When 
examined by electron microscopy, the outer segment of the control rd10 mouse 
retina was mostly disarranged at the age of 21 days, whereas that of the KUS-treated 
rd10 mouse retina was regularly arranged [ 22 ]. 
 Discussion 
 We showed that KUSs, new compounds developed as ATPase inhibitors of VCP, 
have novel functions as “VCP modulators” or “ATP regulators” without apparent 
inhibition of cellular VCP functions. These new “ATP regulators” have strong 
neuroprotective effects  in vivo on retinal photoreceptor cells. The efﬁ cacies were 
apparently correlated with their abilities to suppress ER stress. From the evidence 
that KUSs could prevent the decrease in the cellular ATP level in response to several 
cell death-inducing insults and thereby prevent cell death in pathological condi-
tions, and the evidence that the prevention of early cell death could in turn prevent 
or delay the deterioration of the affected organs, we posit that a reduction of ATP 
levels is a common feature in the affected organs of individuals with incurable 
disorders involving early cell death. Because many proteins require ATP, a reduction 
of ATP levels would contribute to a functional decline in affected cells or organs in 
the early stages of the disease. Reducing ATP consumption by way of KUSs and/or 
enhancing ATP generation by yet-unknown compounds would be a novel strategy 
to retard these processes and thus to prevent or retard the progression of clinical 
manifestations [ 22 ]. 
 References 
  1.  Lin JH, Lavail MM (2010) Misfolded proteins and retinal dystrophies. Adv Exp Med Biol 
664:115–121 
  2.  Jiang H, Xiong S, Xia X (2014) Retinitis pigmentosa-associated rhodopsin mutant T17M 
induces endoplasmic reticulum (ER) stress and sensitizes cells to ER stress-induced cell death. 
Mol Med Rep 9:1737–1742 
  3.  Higashiyama H et al (2002) Identiﬁ cation of  ter94 ,  Drosophila VCP , as a modulator of 
polyglutamine- induced neurodegeneration. Cell Death Differ 9:264–273 
  4.  Kakizuka A (2008) Roles of VCP in human neurodegenerative disorders. Biochem Soc Trans 
36:105–108 
  5.  Watts GD et al (2004) Inclusion body myopathy associated with Paget disease of bone and 
frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 
36:377–381 
  6.  Johnson JO et al (2010) Exome sequencing reveals  VCP mutations as a cause of familial 
ALS. Neuron 68:857–864 
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited.
A. Kakizuka
69
  7.  Manno A, Noguchi M, Fukushi J, Motohashi Y, Kakizuka A (2010) Enhanced ATPase 
activities as a primary defect of mutant valosin-containing proteins that cause inclusion body 
myopathy associated with Paget disease of bone and frontotemporal dementia. Genes Cells 
15:911–922 
  8.  Stolz A, Hilt W, Buchberger A, Wolf DH (2011) Cdc48: a power machine in protein degradation. 
Trends Biochem Sci 36:515–523 
  9.  Meyer H, Bug M, Bremer S (2012) Emerging functions of the VCP/p97 AAA-ATPase in the 
ubiquitin system. Nat Cell Biol 14:117–123 
 10.  Wolf DH, Stolz A (2012) The Cdc48 machine in endoplasmic reticulum associated protein 
degradation. Biochim Biophys Acta 1823:117–124 
 11.  Hirabayashi M et al (2001) VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, 
and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ 8:977–984 
 12.  Kobayashi T, Tanaka K, Inoue K, Kakizuka A (2002) Functional ATPase activity of p97/valo-
sin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in 
neuronally differentiated mammalian PC12 cells. J Biol Chem 277:47358–47365 
 13.  Chou TF et al (2011) Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and 
autophagic protein clearance pathways. Proc Natl Acad Sci U S A 108:4834–4839 
 14.  Zinszner H et al (1998) CHOP is implicated in programmed cell death in response to impaired 
function of the endoplasmic reticulum. Genes Dev 12:982–995 
 15.  Kim R, Emi M, Tanabe K, Murakami S (2006) Role of the unfolded protein response in cell 
death. Apoptosis 11:5–13 
 16.  Naidoo N (2009) ER and aging-Protein folding and the ER stress response. Ageing Res Rev 
8:150–159 
 17.  Gardner BM, Pincus D, Gotthardt K, Gallagher CM, Walter P (2013) Endoplasmic reticulum 
stress sensing in the unfolded protein response. Cold Spring Harb Perspect Biol 5:a013169 
 18.  Gorman AM, Healy SJM, Jager R, Samali A (2012) Stress management at the ER: regulators 
of ER stress-induced apoptosis. Pharmacol Ther 134:306–316 
 19.  Chang B et al (2002) Retinal degeneration mutants in the mouse. Vision Res 42:517–525 
 20.  Ojima Y et al (2010) Restoration of outer segments of foveal photoreceptors after resolution of 
central serous chorioretinopathy. Jpn J Ophthalmol 54:55–60 
 21.  Oishi A et al (2010) The signiﬁ cance of external limiting membrane status for visual acuity in 
age-related macular degeneration. Am J Ophthalmol 150:27–32 
 22.  Ikeda HO et al (2014) Novel VCP modulators mitigate major pathologies of rd10, a mouse 
model of retinitis pigmentosa. Sci Rep 4:5970 
VCP, a Major ATPase in the Cells, as a Novel Drug Target for Currently Incurable…
